Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy.
A Feasibility Trial of PVX7 in advanced cervical cancer patients who have completed primary definitive therapy. * Safety and immunogenicity study * Patients are randomized in a 1:1 ratio to two cohorts, up to 16 patients in each of intramuscular or skin inoculation vaccine injection, up to 32 patients total * Human Immunodeficiency Virus (HIV)-negative patients only * Treatment dose: Arm A: pBI-11 DNA (3 mg) twice via intramuscular (IM) injection, followed by one dose of TA-HPV (2.5x10\^5 pfu) via skin inoculation; Arm B: pBI-11 DNA (3 mg) twice, followed by one dose of TA-HPV (10\^7 pfu) via…
Inclusion Criteria: * Female subjects age 18 years or older with diagnosis of advanced (stage IB1-IVA) HPV+ cervical cancer and have completed primary treatment (consisting of any of the following as per NCCN guideline standard of care: surgical resection, radiation, and/or platinum-based chemotherapy) within the past 12 months. Patients who are recommended to receive anto-PD-1 or anti-PD-L1 therapy after chemoradiation are eligible to enroll and can continue to receive such therapy while receiving study drug. * No history of or current evidence of residual disease or disease recurrence bas…
PVX7 Immunotherapy
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.